Security
Biodexa Pharmaceuticals plc American Depositary Shs · BDRX
BDRXNASDAQotherCurrentCIK 1643918Updated Nov 16, 2026
BDRX price & chart
Loading TradingView…
NASDAQ:BDRX on TradingView ↗About the company
We are a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, including gastrointestinal stromal tumors (“GIST”), familial adenomatous polyposis (“FAP”), non-muscle invasive bladder cancer (“NMIBC”), and type 1 diabetes (“T1D”).
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · GBPSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossGBP | -6,384,000Source | -5,729,000Source | -7,079,000Source | -7,656,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableGBP | 2,629,000Source | -5,975,000Source | 365,000Source | 7,000Source |
| AdjustmentsForIncomeTaxExpenseGBP | -105,000Source | -250,000Source | -406,000Source | -832,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableGBP | -913,000Source | 2,239,000Source | -207,000Source | 356,000Source |
| AdjustmentsForSharebasedPaymentsGBP | 170,000Source | 283,000Source | 28,000Source | 123,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsGBP | 343,000Source | -93,000Source | 164,000Source | 9,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesGBP | -707,000Source | -129,000Source | -845,000Source | -678,000Source |
| InterestPaidClassifiedAsFinancingActivitiesGBP | 14,000Source | — | 13,000Source | 18,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesGBP | — | — | — | 178,000Source |
| ProceedsFromIssuingSharesGBP | 13,749,000Source | 8,312,000Source | 10,427,000Source | 243,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueGBP | — | — | 381,000Source | 699,000Source |
| Additional Financial Items | ||||
| AdministrativeExpenseGBP | 4,836,000Source | 3,793,000Source | 4,342,000Source | 4,542,000Source |
| BasicEarningsLossPerShareGBP/shares | -0Source | -0Source | — | — |
| DepreciationRightofuseAssetsGBP | 136,000Source | 135,000Source | 137,000Source | 166,000Source |
| DilutedEarningsLossPerShareGBP/shares | -0Source | -0Source | — | — |
| FinanceCostsGBP | 229,000Source | 165,000Source | 41,000Source | 53,000Source |
| FinanceIncomeGBP | 2,385,000Source | 3,385,000Source | 570,000Source | 497,000Source |
| IncomeTaxExpenseContinuingOperationsGBP | -105,000Source | -250,000Source | -406,000Source | -832,000Source |
| InterestExpenseOnLeaseLiabilitiesGBP | 10,000Source | 19,000Source | 28,000Source | 43,000Source |
| OtherIncomeGBP | 152,000Source | 31,000Source | 14,000Source | 22,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansGBP | 69,000Source | 67,000Source | 86,000Source | 98,000Source |
| ProfitLossBeforeTaxGBP | -6,489,000Source | -5,979,000Source | -7,485,000Source | -8,488,000Source |
| ProfitLossFromOperatingActivitiesGBP | -8,645,000Source | -9,199,000Source | -8,014,000Source | -8,932,000Source |
| ResearchAndDevelopmentExpenseGBP | 3,961,000Source | 5,437,000Source | 4,067,000Source | 5,111,000Source |
Offerings
Registration 333-299106
Registration 333-297473
Filing attachments
ex4_1.htm · 6-K · 2026-09-15
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE DISTRIBUTED OR TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUAN…
Read attachment ↗ex99_1.htm · 6-K · 2026-09-15
Exhibit 99.1 Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds September 15, 2026 Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an …
Read attachment ↗ex99_1.htm · 6-K · 2026-09-11
Exhibit 99.1 BIODEXA PHARMACEUTICALS PLC INTERIM RESULTS This interim financial information is being furnished under form 6-K Six months ended June 30, 2026 1 September 11, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, today annou…
Read attachment ↗ex4_1.htm · F-1/A · 2026-07-30
EX-4.1 3 ex4_1.htm EXHIBIT 4.1 Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934, as amended of Biodexa Pharmaceuticals PLC (“Biodexa,” “we,” “us,” “our” or the “Company”) is a summary of the rights of our issued share capital and certain provisions of our articles of association. This summary does not purport to be complete and is qualified in …
Read attachment ↗ex99_1.htm · 6-K · 2026-07-29
Exhibit 99.1 July 29, 2026 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces that at its General Meeting held earlier today, all four resolutions put to the Company’s shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at…
Read attachment ↗ex4_1.htm · F-1 · 2026-07-15
EX-4.1 2 ex4_1.htm EXHIBIT 4.1 Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934, as amended of Biodexa Pharmaceuticals PLC (“Biodexa,” “we,” “us,” “our” or the “Company”) is a summary of the rights of our issued share capital and certain provisions of our articles of association. This summary does not purport to be complete and is qualified in …
Read attachment ↗